Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults.
Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.
With the green signal to Lundbeck, it becomes a new member in the Migraine treatment market, which is already swarming with the new therapies by pharma giants including Teva, Amgen and Eli Lilly.
Vyepti is the very first intravenous medication to receive the approval and will be available to patients from April this year. A humanized monoclonal antibody, Vyepti binds...
